Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP265721.RA5whqit98sl6GnFw3noSJLEzrXcGeitxiK2XPwoK4afc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP265721.RA5whqit98sl6GnFw3noSJLEzrXcGeitxiK2XPwoK4afc130_assertion type Assertion NP265721.RA5whqit98sl6GnFw3noSJLEzrXcGeitxiK2XPwoK4afc130_head.
- NP265721.RA5whqit98sl6GnFw3noSJLEzrXcGeitxiK2XPwoK4afc130_assertion description "[Monitoring of minimal residual disease (MRD) by quantification of BCR-ABL1 transcript levels has become a main part of the management of patients with BCR-ABL1-positive acute lymphoblastic leukemia (ALL) in treatment with tyrosine kinase inhibitors (TKIs).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP265721.RA5whqit98sl6GnFw3noSJLEzrXcGeitxiK2XPwoK4afc130_provenance.
- NP265721.RA5whqit98sl6GnFw3noSJLEzrXcGeitxiK2XPwoK4afc130_assertion evidence source_evidence_literature NP265721.RA5whqit98sl6GnFw3noSJLEzrXcGeitxiK2XPwoK4afc130_provenance.
- NP265721.RA5whqit98sl6GnFw3noSJLEzrXcGeitxiK2XPwoK4afc130_assertion SIO_000772 24630366 NP265721.RA5whqit98sl6GnFw3noSJLEzrXcGeitxiK2XPwoK4afc130_provenance.
- NP265721.RA5whqit98sl6GnFw3noSJLEzrXcGeitxiK2XPwoK4afc130_assertion wasDerivedFrom befree-20150227 NP265721.RA5whqit98sl6GnFw3noSJLEzrXcGeitxiK2XPwoK4afc130_provenance.
- NP265721.RA5whqit98sl6GnFw3noSJLEzrXcGeitxiK2XPwoK4afc130_assertion wasGeneratedBy ECO_0000203 NP265721.RA5whqit98sl6GnFw3noSJLEzrXcGeitxiK2XPwoK4afc130_provenance.